Cites

CITES is a unique deep-tech incubator and seed fund in Argentina with a specific focus on patentable healthcare technologies, including biotech, medical devices, and pharma. Headquartered in Sunchales rather than Buenos Aires, the fund operates from one of Argentina’s most distinctive provincial innovation ecosystems, anchored by the Sancor Seguros cooperative network. Stage focus is pre-seed and seed with checks in the $250k to $1M range, and AI is a stated focus area. This is one of very few credible early-stage life sciences and patentable-tech investors in Argentina or wider Spanish-speaking LatAm. The right founder for CITES is a scientist-founder with a defensible IP position, often emerging from CONICET, university research labs across Argentina, or industry R&D, with a credible path to global market relevance through US or European clinical and regulatory pathways. Biotech, medtech, diagnostic device, and patentable pharma teams all fit. The wrong founder is a digital health software team without a hardware or patentable technology component, a US-pedigreed biotech using Argentina only for capital, or a clinical-stage company needing tens of millions per round; CITES operates at the seed scale where early proof-of-concept and IP filing milestones are the relevant unlocks. Intro paths run through Argentine science and translation networks: CONICET tech transfer offices, the Universidad de Buenos Aires and Universidad Nacional de Cordoba networks, regional accelerators such as GRIDX and Embarca, and through US and European biotech investors who occasionally co-invest at later stages including Humboldt Fund and SP Ventures. In the pitch, lead with the science: target validation, mechanism, IP strategy, the publication record of the founding team, and the realistic preclinical or device-prototype milestone the round will fund. Be specific about ANMAT pathways for Argentine regulatory and the FDA or CE Mark strategy for global markets, since Argentine-only therapeutic or device markets do not generate venture returns. Show realistic capital intensity and a credible Series A syndicate hypothesis beyond CITES. Caveats are real and structural. Argentine biotech faces meaningful FX, capital control, and IP-export friction, and founders should incorporate in Delaware or another acceptable jurisdiction early to align with downstream investors. CITES has built real expertise in navigating these challenges, but founders should not underestimate the complexity. For credentialed Argentine science teams, CITES is one of the few real venture options in the country.